Article Text

Download PDFPDF
The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans
  1. Alessia Alunno1,
  2. Francesco Carubbi2,
  3. Sara Caterbi1,
  4. Onelia Bistoni1,
  5. Elena Bartoloni1,
  6. Roberto Giacomelli2,
  7. Roberto Gerli1
  1. 1Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy
  2. 2Rheumatology Unit, Clinical Science and Biotechnology Department, University of L'Aquila, L'Aquila, Italy
  1. Correspondence to Professor Roberto Gerli, Rheumatology Unit, Department of Medicine, University of Perugia, Perugia I-06126, Italy; roberto.gerli{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the article by Lin et al that provided the clue for a pathogenic role of T helper (h) 17 cells in the development of experimental Sjögren's syndrome (SS).1 In particular, interleukin (IL)-17 knockout C57BL/6 mouse immunised with salivary glands (SGs) proteins does not display clinical, histological and serological features of SS as the wild type counterpart.1 Previous studies reported that the infusion of adenovirus vectors expressing IL-17 into SGs, via retrograde cannulation, was able to induce clinical, serological and histological features of SS in non-susceptible mice, thereby suggesting a pathogenic role of this cytokine in the induction of glandular damage in SS.2 To date, it is still a matter of …

View Full Text


  • Contributors All authors provided substantial contributions to the conception or design of the work, the acquisition, analysis, or interpretation of data for the work. AA wrote the manuscript and all coauthors critically revised it for important intellectual content. All authors approved the version to be published.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Comitato Etico delle Aziende Sanitarie (CEAS) dell'Umbria.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles